Information Provided By: 
Fly News Breaks for March 8, 2016
FOLD
Mar 8, 2016 | 07:24 EDT
Janney Capital analyst Roy Buchanan upgraded Amicus to Buy and raised his fair value estimate to $12 from $10. The analyst is not sure what the FDA will do with migalastat in Fabry's, but expects a positive CHMP opinion in early April. Buchanan also said he might been too pessimistic on Zorblisa for epidermolysis bullosa, currently in Phase III and increase his probability of success for that program 60% from 40%.
News For FOLD From the Last 2 Days
There are no results for your query FOLD
